Sentinel Node Biopsy in Endometrial Cancer

Trial Title: Sentinel Node Biopsy in Endometrial Cancer

NCT ID: NCT01564264

Condition: Uterine Neoplasms
Sentinel Lymph Node Biopsy

Conditions: Official terms:
Endometrial Neoplasms
Uterine Neoplasms

Conditions: Keywords:
Uterine Neoplasms
Sentinel Lymph Node Biopsy

Study type: Interventional

Study phase: N/A

Overall status: Unknown status

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Diagnostic

Masking: None (Open Label)

Intervention:

Intervention type: Procedure
Intervention name: Sentinel Lymph Node Biopsy
Description: Sentinel node biopsy after injections of 0.4 mci of Technetium 99 in the cervix and 4 mL of Patent Blue into the myometrium followed by standard retroperitoneal lymph node dissection
Arm group label: Sentinel Node Biopsy

Summary: The purpose of this study is to determine if there is a difference between the lymphatic drainage of the cervix and corpus of the uterus after injecting a radiocolloid in the cervix and blue dye in the corpus of the uterus and to investigate the identification rate of sentinel nodes using this technique in patients with cancer of the uterus.

Detailed description: About 20 percent of women diagnosed with uterine cancer have spread outside of the uterus, mainly to the lymph nodes. If these metastases are recognized these women can still be cured with chemotherapy and radiation. Unfortunately different kind of imaging are not very sensitive in identifying patients with lymph node metastases and currently a complete removal of the lymph nodes in the pelvis and around the aorta is the gold standard diagnostic test. Sentinel node biopsy (SLNB) is a surgical technique that aims to identify the nodes that drain specifically the area were the tumor is located. A tracer is injected around the tumor and then the locoregional lymph nodes are tested for the presence of this tracer (blue dye and a radioactive substance). If the sentinel lymph node does not contain cancer, then there is a high likelihood that the cancer has not spread to any other area of the body.The benefits of doing sentinel node biopsy is that it decreases the potential complications associated with the removal of all the lymph nodes. This technique is the standard treatment for other cancers as breast cancer and melanoma and is emerging as a promising technique in gynecological cancers. There is no agreement regarding the best technique to do SLNB in women with uterine cancer and this procedure is still at the stage of determining feasibility. Since 1996, there have been publications aiming to determine the most appropriate way to do sentinel node in uterine cancer. As the uterus cannot be reached preoperatively for tracer injection, the standard approach for other tumor sites of preoperative peritumoral injection of Technetium 99 followed by intraoperative injection of blue dye has needed to be modified. Blue dye with or without a radiocolloid have been administered either subserously (the uterus outer layer), cervically, dually, and hysteroscopically with a wide range of results in terms of identification rates of sentinel nodes. Certain factors as site of injection, volume and number of injections, interval time since injection to identification of sentinel nodes and surgical approach as laparotomy versus laparoscopy have been associated with the likelihood of identifying these nodes. This study plans to determine the pattern of lymphatic drainage for the cervix and corpus of the uterus by injecting a different tracer in these 2 sites and also to incorporate all factors that have been proved to be associated with a better identification rate of sentinel nodes in a protocol in order to determine if this technique is feasible and reliable.

Criteria for eligibility:
Criteria:
Inclusion Criteria: 1. Women older than 18 years old 2. Endometrial cancer 3. Histologies: Grade 2 and 3 endometrioid adenocarcinoma, clear cell and papillary serous carcinoma 4. Suitable candidates for surgery 5. Clinically stage 1 or confined to the uterus Exclusion Criteria: 1. Grade 1 endometrioid adenocarcinoma 2. Metastatic disease

Gender: Female

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Juravinski Hospital, Juravinski Cancer Centre, McMaster University

Address:
City: Hamilton
Zip: L8V 5C2
Country: Canada

Status: Recruiting

Contact:
Last name: Waldo G Jimenez, MD MSc

Phone: (905) 389-5688
Email: Waldo.Jimenez@jcc.hhsc.ca

Contact backup:
Last name: Laurie Elit, MD MSc

Phone: (905) 389-5688
Email: Laurie.Elit@jcc.hhsc.ca

Investigator:
Last name: Waldo G Jimenez, MD MSc
Email: Principal Investigator

Start date: November 2012

Completion date: December 2014

Lead sponsor:
Agency: Hamilton Health Sciences Corporation
Agency class: Other

Collaborator:
Agency: Juravinski Cancer Centre Foundation
Agency class: Other

Source: Hamilton Health Sciences Corporation

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT01564264